Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Augusta University

Neither a doctor nor a teaching hospital

Research payments

$2,967,558

340 payments

Through program year 2025, Augusta University is reported as receiving $2,967,558 in research payments, across 340 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $102,525 4
2024 Research $126,476 34
2023 Research $165,843 21
2022 Research $655,815 70
2021 Research $1,166,920 95
2020 Research $596,433 91
2019 Research $153,546 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Seattle Genetics, Inc. $1,467,483 147 payments
  2. Merck Sharp & Dohme Corporation $430,900 73 payments
  3. Vertex Pharmaceuticals Incorporated $306,253 13 payments
  4. E.R. Squibb & Sons, L.L.C. $165,514 10 payments
  5. BeiGene, Ltd. $111,096 3 payments
  6. Jazz Pharmaceuticals Inc. $97,813 1 payment
  7. Novartis Pharmaceuticals Corporation $75,527 4 payments
  8. Karyopharm Therapeutics Inc. $74,000 3 payments
  9. Regeneron Pharmaceuticals, Inc. $66,823 17 payments
  10. Insmed, Inc. $53,555 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer $565,564 19 payments
  2. Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen $368,886 16 payments
  3. Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer $340,040 71 payments
  4. A phase I,II trial of pembrolizumab and poly ICLC in patients with recurrent metastatic mismatch repair-proficient MRP colon cancer $154,050 2 payments
  5. A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $128,003 4 payments
  6. Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib $105,732 18 payments
  7. V-Fast: A Phase 1B Master Trial to Investigate Cpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia $97,813 1 payment
  8. A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $81,197 10 payments
  9. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) $79,708 4 payments
  10. A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2Nd Line Chronic Phase - Chronic Myelogenous Leukemia $60,302 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record